Mutations in the insulin promoter factor-1 gene in late-onset type 2 diabetes mellitus

A F Reis, W-Z Ye, D Dubois-Laforgue, C Bellanné-Chantelot, J Timsit and G Velho

INSERM Unité 342, Institut Cochin de Génétique Moléculaire, Paris, France, 1Service d’Immunoologie Clinique, Hôpital Necker-Enfants Malades, Paris, France and 2Fondation Jean Dausset Centre d’Etude du Polymorphisme Humain, Paris, France

(Correspondence should be addressed to G Velho, INSERM U-342, Hôpital Saint Vincent-de-Paul, 82 Avenue Denfert Rochereau, 75014 Paris, France; Email: gvelho@infobiogen.fr)

Abstract

Objective: Insulin promoter factor-1 (IPF-1) is a transcription factor expressed in pancreatic beta cells. Following the identification of missense variants in the coding regions of the IPF-1 gene, in subjects selected for a strong family history of type 2 diabetes, the aim of our study was to evaluate the prevalence of these variants in the common form of type 2 diabetes.

Methods: Three variants (C18R, Q59L and D76N) were screened by PCR-RFLP in a group of 296 unrelated French late-onset type 2 diabetic subjects consecutively recruited in a diabetes department of a university hospital, regardless of family history of diabetes.

Results: The C18R and Q59L variants were each found in 0.37% of the diabetic patients, and in none of 147 controls. We did not detect the D76N variant, which was the most frequent variant in subjects with a strong family history of diabetes, in patients or controls.

Conclusions: We have observed a combined prevalence of missense variants in the coding region of the IPF-1 gene of around 1%, in unselected patients with the common form of late-onset type 2 diabetes. The prevalence of these variants in subjects with a strong family history of type 2 diabetes had been found to be as high as ~6%. These differences in prevalence might be related to differences in the clinical profile of patients, such as age of onset of diabetes and associated obesity, as well as a family history of diabetes.

European Journal of Endocrinology 143 511–513

Introduction

Mutations in five genes coding for transcription factors expressed in pancreatic beta cells are associated with maturity onset diabetes of the young (MODY), a monogenic familial form of diabetes mellitus characterised by early-onset, autosomal dominant transmission, and insulin secretion defects (1). These transcription factors are the hepatocyte nuclear factor 4 alpha (HNF-4α/MODY1) (2), hepatocyte nuclear factor 1 alpha (HNF-1α/MODY3) (3), insulin promoter factor-1 (IPF1/MODY4) (4), hepatocyte nuclear factor 1 beta (HNF-1β/MODY5) (5), and neuroD1/beta2 (6).

The homeodomain transcription factor IPF-1 (also known as PDX-1, IDX-1 or STF-1) is involved in the early embryonic development of the pancreas, and in the transcriptional regulation of endocrine pancreas-related genes such as insulin, glucose transporter 2 (GLUT2) and glucokinase (7). Mutations in IPF-1 are a rare cause of MODY (4, 8–10). A frameshift mutation (Pro63fsdelC) was described in one family in which it was associated with pancreatic agenesis in a homozygous carrier (11), and with a phenotype ranging from normal to impaired glucose tolerance, to overt non-insulin-dependent diabetes in heterozygous carriers (4). Recently, an in-frame insertion of a proline (InsCCG243) was found to co-segregate with diabetes and/or an insulin secretion defect in two families with an autosomal dominant-like transmission (12).

Data on the role of IPF-1 mutation in the more frequent polygenic forms of type 2 (non-insulin-dependent) diabetes with late age of onset are scarce. Four missense variants in the coding region of IPF-1 were observed in British (C18R, D76N, R197H) (13) and French (Q59L, D76N) (12) subjects with late-onset type 2 diabetes, selected for a strong family history of diabetes. Their prevalence ranged from 0.51% to 4.7% in these populations and they were also observed in British subjects with MODY in whom mutations in HNF-4α, HNF-1α, HNF-1β and glucokinase genes had been excluded (MODYx) (13). The prevalence of all variants taken together was significantly higher in diabetic subjects (late-onset and MODY combined) than in controls. However, they co-segregated only partially...
Table 1 Demographic and clinical profile of patients and controls. Data are expressed as means ± s.d.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects (n)</td>
<td>296</td>
<td>143</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>59%/41%</td>
<td>50%/50%</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62 ± 12</td>
<td>61 ± 16</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>29.3 ± 5.9</td>
<td></td>
</tr>
<tr>
<td>Age of diagnosis of diabetes (years)</td>
<td>50 ± 11</td>
<td>–</td>
</tr>
<tr>
<td>Duration of diabetes (years)</td>
<td>13 ± 9</td>
<td>–</td>
</tr>
<tr>
<td>Treatment (OHA/insulin)</td>
<td>59%/41%</td>
<td>–</td>
</tr>
<tr>
<td>Prevalence of obesity</td>
<td>38%</td>
<td>–</td>
</tr>
<tr>
<td>Prevalence of hypertension</td>
<td>67%</td>
<td>–</td>
</tr>
<tr>
<td>Total cholesterol &gt; 6 mmol/l (%)</td>
<td>34%</td>
<td>–</td>
</tr>
<tr>
<td>Triglycerides &gt; 2 mmol/l (%)</td>
<td>51%</td>
<td>–</td>
</tr>
</tbody>
</table>

OHA, oral hypoglycaemic agents.

Obesity was defined as BMI ≥ 30 kg/m².

Hypertension was defined as: 1) systolic blood pressure (SBP) greater than 140 mmHg and/or a diastolic blood pressure (DBP) greater than 85 mmHg, 2) SBP and/or DBP below these values in the presence of antihypertensive medication and history of hypertension.

Results

The C18R variant was seen only in one diabetic subject out of the 272 tested (0.37%) and in none of 147 controls. The carrier is a 62-year-old woman, diagnosed at the age of 51 years and treated since then by oral hypoglycaemic agents, and without any known family history of diabetes. She is obese (body mass index (BMI) 36.4 kg/m²), hypertensive and presents high triglycerides levels. The Q59L variant was also observed in only one diabetic subject out of 272 (0.37%) and in none of the controls. The carrier is a 71-year-old woman, diagnosed at the age of 67 years and treated since then by oral hypoglycaemic agents. She reports a family history of diabetes (mother and paternal grandmother). The patient is obese (BMI 34.8 kg/m²), hypertensive and has documented coronary heart disease. The D76N mutation was not found in any of the 296 diabetic subjects nor in the controls.

Discussion

The prevalences of the C18R and Q59L variants in our cohort are similar to those reported in the studies of diabetic patients with a strong family history of diabetes, confirming that they are very rare. The C18R variant was observed in 0.51% of the probands and in none of the controls in the British study (13), and the Q59L variant was observed in 0.52% of the probands and in none of the controls in the French study (12). We have not tested the R197H variant, seen only in one British patient. For the D76N variant, which was not found in patients or controls from our cohort, it was observed in 2.06% of the probands and 1.04% of the controls in the British study (13) and in 4.68% of the probands and in 0.43% of the controls in the French study (12). Incidentally, we have observed this variant in the proband from a Brazilian MODY family, who was subsequently found to carry also an HNF-1α/MODY3 mutation (data not shown). However, the HNF-1α mutation but not the IPF-1 D76N variant co-segregated with diabetes in that family.

These differences in prevalence of the D76N variant might be related to the different clinical profiles of diabetes in the three studies. Unlike our patients,
subjects in the French and British studies were selected for a strong family history of diabetes, and all had at least one first-degree relative with type 2 diabetes. Forty-three percent of our patients reported a history of diabetes in a first-degree relative. However, we have not tested these family members, and thus this information is less reliable than that obtained in the other studies. Moreover, the average age of diagnosis of diabetes and the BMI were both higher in our patients (50 ± 11 years and 29.3 ± 5.9 kg/m² respectively; means ± s.d.) and they were less often treated by insulin (41%) than the French subjects with familial type 2 diabetes studied by Hani and co-workers (42%). These observations suggest that they may represent different sub-sets of type 2 diabetes patients, despite the common geographical origin of both samples. In the British study, the age of diagnosis of diabetes was higher (56 ± 9 years), the BMI intermediate (28.1 ± 4.9 kg/m²) and the frequency of treatment by insulin lower (36%) than in our study and in the French study of familial type 2 diabetes. It is noteworthy that the prevalence of the D76N variant in the British study was less than half of that observed in the French study. It is also possible that these differences in the prevalence of the D76N variant might be related to bias due to the relatively small number of diabetic subjects tested in all these investigations (206 and 192 subjects in the British (13) and in the French (12) study respectively, and 296 in ours). Thus, we cannot exclude either a type 1 error (observed frequency higher than the true frequency) or a type 2 error (observed frequency lower than the true frequency). In this regard, the D76N variant was recently found in only one out of 200 (0.5%) Danish subjects with late-onset type 2 diabetes, of whom at least 33% had a strong family history of diabetes (10). No other missense mutation was found in that study, except for an A140T variant showing no co-segregation with diabetes in a Danish MODY family. Moreover, the two variants were not associated with decreased transcriptional activation of the insulin gene promoter in vitro (10).

In conclusion, variants in the IPF-1 gene may predispose to type 2 diabetes, probably in a polygenic and multifactorial context. Although their combined prevalence was found to be as high as ~6% in subjects selected for a strong familial history of type 2 diabetes (12), our data suggest a much lower prevalence, around 1%, in unselected patients with the common form of late-onset type 2 diabetes.

Acknowledgements

This work was supported by grants from INSERM/Merck, Sharp Dhome and Chibret for research in Clinical Investigation Centres (INSERM CIC 9303 NEM), the 'Fondation pour la Recherche Médicale', and Lilly, France. AF Reis is supported by a doctoral grant from CAPES, Brasilia, Brazil, and WZ Ye by a grant from AJD, France.

References


Received 4 April 2000
Accepted 29 June 2000